Kahira Pharmaceuticals & Chemical Industries Company (EGX:CPCI)
Egypt
· Delayed Price · Currency is EGP 250.64
-3.62 (-1.42%)
At close: Mar 5, 2026
EGX:CPCI Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 2,281 | 2,079 | 1,361 | 1,005 | 1,112 | 1,062 | Upgrade
|
| Revenue Growth (YoY) | 33.69% | 52.80% | 35.38% | -9.61% | 4.71% | 5.11% | Upgrade
|
| Cost of Revenue | 1,471 | 1,288 | 843.19 | 767.94 | 785.17 | 793.91 | Upgrade
|
| Gross Profit | 809.77 | 791.47 | 517.66 | 237.3 | 326.95 | 268.13 | Upgrade
|
| Selling, General & Admin | 132.76 | 138.06 | 116.67 | 103.71 | 101.75 | 87.62 | Upgrade
|
| Other Operating Expenses | 79.68 | 85.54 | 115.32 | 56.85 | 33.11 | 24.18 | Upgrade
|
| Operating Expenses | 212.45 | 223.6 | 231.99 | 160.56 | 134.86 | 111.8 | Upgrade
|
| Operating Income | 597.33 | 567.86 | 285.67 | 76.74 | 192.08 | 156.33 | Upgrade
|
| Interest Expense | -16.35 | -13.54 | -18.94 | -3.47 | - | - | Upgrade
|
| Interest & Investment Income | 22.26 | 21.71 | 14.68 | 4.36 | 6.87 | 3.89 | Upgrade
|
| Currency Exchange Gain (Loss) | -12.74 | -12.74 | 27.81 | 45.83 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 9.13 | 9.13 | 6.13 | 4.01 | 15.14 | 2.84 | Upgrade
|
| EBT Excluding Unusual Items | 599.63 | 572.43 | 315.35 | 127.48 | 214.1 | 163.06 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.22 | 2.22 | -0 | 0.08 | - | - | Upgrade
|
| Pretax Income | 601.85 | 574.64 | 315.35 | 127.56 | 214.1 | 163.06 | Upgrade
|
| Income Tax Expense | 134.95 | 130.92 | 69.24 | 30.47 | 48.35 | 38.75 | Upgrade
|
| Earnings From Continuing Operations | 466.89 | 443.72 | 246.11 | 97.09 | 165.74 | 124.3 | Upgrade
|
| Net Income | 466.89 | 443.72 | 246.11 | 97.09 | 165.74 | 124.3 | Upgrade
|
| Net Income to Common | 466.89 | 443.72 | 246.11 | 97.09 | 165.74 | 124.3 | Upgrade
|
| Net Income Growth | 25.72% | 80.29% | 153.48% | -41.42% | 33.34% | 13.89% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| EPS (Basic) | 31.21 | 29.71 | 16.48 | 6.50 | 11.10 | 8.32 | Upgrade
|
| EPS (Diluted) | 31.21 | 29.71 | 16.48 | 6.50 | 11.10 | 8.32 | Upgrade
|
| EPS Growth | 25.37% | 80.29% | 153.48% | -41.42% | 33.34% | 13.89% | Upgrade
|
| Free Cash Flow | 248.2 | 239.25 | 46.65 | 9.45 | 34.52 | 138.57 | Upgrade
|
| Free Cash Flow Per Share | 16.59 | 16.02 | 3.12 | 0.63 | 2.31 | 9.28 | Upgrade
|
| Dividend Per Share | 16.740 | 16.740 | 12.830 | 5.000 | 5.000 | 4.000 | Upgrade
|
| Dividend Growth | 30.48% | 30.48% | 156.60% | - | 25.00% | 49.25% | Upgrade
|
| Gross Margin | 35.51% | 38.06% | 38.04% | 23.61% | 29.40% | 25.25% | Upgrade
|
| Operating Margin | 26.19% | 27.31% | 20.99% | 7.63% | 17.27% | 14.72% | Upgrade
|
| Profit Margin | 20.47% | 21.34% | 18.09% | 9.66% | 14.90% | 11.70% | Upgrade
|
| Free Cash Flow Margin | 10.88% | 11.51% | 3.43% | 0.94% | 3.10% | 13.05% | Upgrade
|
| EBITDA | 641.44 | 599.51 | 290.99 | 88.3 | 207.25 | 156.77 | Upgrade
|
| EBITDA Margin | 28.13% | 28.83% | 21.38% | 8.78% | 18.64% | 14.76% | Upgrade
|
| D&A For EBITDA | 44.11 | 31.65 | 5.32 | 11.56 | 15.17 | 0.44 | Upgrade
|
| EBIT | 597.33 | 567.86 | 285.67 | 76.74 | 192.08 | 156.33 | Upgrade
|
| EBIT Margin | 26.19% | 27.31% | 20.99% | 7.63% | 17.27% | 14.72% | Upgrade
|
| Effective Tax Rate | 22.42% | 22.78% | 21.96% | 23.88% | 22.58% | 23.77% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.